- Total product sales of €30.5 million
- Cash position of €105.3 million as of end March 2026, excluding proceeds from successful reserved offering completed in April 2026
- Program launched in April to further reduce operating expenses
- Pfizer expected to file regulatory submissions for Lyme disease vaccine candidate
Lyon (France), May 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its financial results for the first quarter ended March 31, 2026, provided key corporate updates, and updated its 2026 financial guidance. The condensed consolidated interim financial results are available on the Company’s website (Financial Reports – Valneva).
Valneva will provide a live webcast of its first quarter 2026 results conference call beginning at 3 p.m. CEST/9 a.m. EDT today. This webcast will also be available on the Company’s website. Please refer to this link: https://edge.media-server.com/mmc/p/xbkzgkz7
To access the full release, please click on the PDF below.